Sign in
4

Changes in Ownership

Contineum Therapeutics, Inc. Filed Acc 0001628280-26-052031

CEO and President sold 2,500 shares at $16.01 ($40,029)

  • CEO and President acquired 2,500 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Stengone Carmine N. · CEO and President

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-08-03 Exercise or conversion : show line 1 in the form 10b5-1 +2,500 $1.01 $2,525 19,717 D
2026-08-03 Sale : show line 2 in the form 10b5-1 −2,500 $16.01 $40,029 17,217 D
Open-market sales · 2,500 sh · avg $16.01 · $40,029

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-08-03 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −2,500 276,930 D
Loading xslF345X06/wk-form4_1785795270.xml…